Interestingly, while the combined treatment with PLX4720 and ABT-737 induced apoptosis in melanoma cell lines established from pre-therapy lesions, this effect was lost in cell lines from post-therapy lesions of patients who developed resistance to the BRAF inhibitor (143). The gene discussed is BRAF; the disease is melanoma.